RESEARCH

Directly or indirectly, cancer will touch everyone's lives. There is no greater or more worthwhile challenge than the ongoing battle to develop and improve anti-cancer treatments, for everyone's sake.

programme of research


University of Bradford

2002/3

YCR Laboratory of Drug Design
The Tom Connors Cancer Research Centre
Director: Professor T.C. Jenkins


T.C. Jenkins
S.L. Moores
ENACT developments in NQO1/NQO2 enzyme-directed therapies


T.C. Jenkins
T. Brown
G.P. Wilkinson
Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) as DNA-targeted drugs


T.C. Jenkins
J.R.P. Arnold
P.J. Perry
T.A. Norris
T. Brown
Drug targeting of high-order DNA systems


P.J. Perry
J.R.P. Arnold
T.C. Jenkins
Activation of p53 response through inhibition of the p53-MDM2 complex


T.C. Jenkins
P.J. Perry
T.A. Norris
Mutagenic profiling and optimisation of DNA-targeted drugs

P.J. Perry
J.R.P. Arnold
T.C. Jenkins
Novel functionalised chalcones as microtubule inhibitors


P.J. Perry
T.C. Jenkins
CYP1B1-activated prodrugs for use in anti-cancer chemotherapy


T.C. Jenkins
P.J. Perry
J.R.P. Arnold
Structural analysis of chalcones by X-ray crystallographic, molecular modelling and solution NMR techniques

School of Pharmacy
Head of Department: Professor B. Costall


S. Carrington
J.E. Brown
H. Mackay
Structure-activity studies on novel DNA affinic compounds
incorporating oestrogen-receptor ligand, polyamine and antineoplastic moieties